- Report
- April 2025
- 356 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- August 2024
- 141 Pages
Global
From €2729EUR$2,999USD£2,340GBP
- Clinical Trials
- June 2024
- 240 Pages
Global
From €2730EUR$3,000USD£2,341GBP
- Report
- August 2024
- 187 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- July 2024
- 183 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- September 2019
- 30 Pages
China
From €2002EUR$2,200USD£1,716GBP
- Report
- August 2022
- 118 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- March 2021
- 102 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Drug Pipelines
- April 2024
- 50 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Report
- March 2024
- 257 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Report
- January 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,238GBP
- Report
- February 2024
- 137 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- May 2023
- 236 Pages
Global
From €3276EUR$3,600USD£2,809GBP
- Report
- April 2021
- 120 Pages
Global
€20022EUR$22,000USD£17,165GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- February 2023
- 392 Pages
Global
From €3249EUR$3,570USD£2,785GBP

Cytarabine is a chemotherapy drug used to treat acute myeloid leukemia (AML) and other types of leukemia. It is a nucleoside analog, which means it works by interfering with the growth of cancer cells. Cytarabine is usually given intravenously or as an injection into the spinal fluid. It is often used in combination with other drugs to treat AML. Cytarabine is also used to treat other types of cancer, such as lymphoma and multiple myeloma.
Cytarabine is a widely used drug in the treatment of leukemia, and is available in both generic and branded forms. It is typically prescribed in combination with other drugs, such as daunorubicin and idarubicin. The drug is available in both oral and injectable forms, and is often used in combination with other drugs to treat AML.
The cytarabine market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and Teva Pharmaceuticals. Show Less Read more